Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387694665> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4387694665 endingPage "948" @default.
- W4387694665 startingPage "943" @default.
- W4387694665 abstract "Background: An authorized generic drug has identical ingredients as the brand-name drug but marketed as a generic version by the innovator company with a lower cost. A branded generic drug is an imitation of the brand-name medication whose patent has expired. The active elements of a branded generic medicine are the same as those of the original drug, however the inactive ingredients may differ. Objective: To assess the effectiveness of the branded generic atorvastatin (Lipostat®), compared to the authorized generic atorvastatin (Xarator®) in decreasing low density lipoprotein cholesterol (LDL-C) levels. Materials and Methods: The present study was a prospective cohort study that included patients who had been taking the authorized generic atorvastatin (Xarator®) 40 mg once daily for at least three months. The authorized generic atorvastatin (Xarator®) was switched to branded generic atorvastatin (Lipostat®) 40 mg once daily for the next three months. Blood chemistry including lipid profile were evaluated before and three months after the transition from Xarator® to Lipostat®. Results: Of the 61 patients, mean age was 67.0±9.9 years, and 45 (73.7%) were male. The two most common comorbidities included coronary artery disease in 80.3% and hypertension in 60.7%. At three months after switching to branded generic atorvastatin, the mean total cholesterol changed from 133.6±28.8 to 130.0±25.8 mg/dL, the triglyceride changed from 123.3±78.3 to 115.6±70.1 mg/dL, and the LDL-C changed from 68.8±24.1 to 65.5±20.3 mg/dL, thus, they were not significantly different compared to the baseline. There were also no significant differences in adverse events between Lipostat® and Xarator®. Conclusion: Branded generic atorvastatin (Lipostat®) is as effective as the authorized generic atorvastatin (Xarator®) in lowering LDL-C levels. Keywords: Atorvastatin; Authorized generic drug; Branded generic atorvastatin; Low-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Statin" @default.
- W4387694665 created "2023-10-18" @default.
- W4387694665 date "2023-10-16" @default.
- W4387694665 modified "2023-10-18" @default.
- W4387694665 title "The Comparative Effectiveness between Branded Generic Atorvastatin (Lipostat®) and Authorized Generic Atorvastatin (Xarator®): A Prospective Cohort Study" @default.
- W4387694665 doi "https://doi.org/10.35755/jmedassocthai.2023.10.13898" @default.
- W4387694665 hasPublicationYear "2023" @default.
- W4387694665 type Work @default.
- W4387694665 citedByCount "0" @default.
- W4387694665 crossrefType "journal-article" @default.
- W4387694665 hasConcept C10138342 @default.
- W4387694665 hasConcept C112698675 @default.
- W4387694665 hasConcept C126322002 @default.
- W4387694665 hasConcept C144133560 @default.
- W4387694665 hasConcept C188816634 @default.
- W4387694665 hasConcept C2776396487 @default.
- W4387694665 hasConcept C2776473838 @default.
- W4387694665 hasConcept C2777482532 @default.
- W4387694665 hasConcept C2778163477 @default.
- W4387694665 hasConcept C2778913445 @default.
- W4387694665 hasConcept C2780035454 @default.
- W4387694665 hasConcept C2992181568 @default.
- W4387694665 hasConcept C71924100 @default.
- W4387694665 hasConcept C72563966 @default.
- W4387694665 hasConcept C84309077 @default.
- W4387694665 hasConcept C98274493 @default.
- W4387694665 hasConceptScore W4387694665C10138342 @default.
- W4387694665 hasConceptScore W4387694665C112698675 @default.
- W4387694665 hasConceptScore W4387694665C126322002 @default.
- W4387694665 hasConceptScore W4387694665C144133560 @default.
- W4387694665 hasConceptScore W4387694665C188816634 @default.
- W4387694665 hasConceptScore W4387694665C2776396487 @default.
- W4387694665 hasConceptScore W4387694665C2776473838 @default.
- W4387694665 hasConceptScore W4387694665C2777482532 @default.
- W4387694665 hasConceptScore W4387694665C2778163477 @default.
- W4387694665 hasConceptScore W4387694665C2778913445 @default.
- W4387694665 hasConceptScore W4387694665C2780035454 @default.
- W4387694665 hasConceptScore W4387694665C2992181568 @default.
- W4387694665 hasConceptScore W4387694665C71924100 @default.
- W4387694665 hasConceptScore W4387694665C72563966 @default.
- W4387694665 hasConceptScore W4387694665C84309077 @default.
- W4387694665 hasConceptScore W4387694665C98274493 @default.
- W4387694665 hasIssue "10" @default.
- W4387694665 hasLocation W43876946651 @default.
- W4387694665 hasOpenAccess W4387694665 @default.
- W4387694665 hasPrimaryLocation W43876946651 @default.
- W4387694665 hasRelatedWork W1510749525 @default.
- W4387694665 hasRelatedWork W1774723023 @default.
- W4387694665 hasRelatedWork W2084618851 @default.
- W4387694665 hasRelatedWork W2095722916 @default.
- W4387694665 hasRelatedWork W2150638694 @default.
- W4387694665 hasRelatedWork W2370960288 @default.
- W4387694665 hasRelatedWork W2585448320 @default.
- W4387694665 hasRelatedWork W2624603992 @default.
- W4387694665 hasRelatedWork W2789864959 @default.
- W4387694665 hasRelatedWork W3121843601 @default.
- W4387694665 hasVolume "106" @default.
- W4387694665 isParatext "false" @default.
- W4387694665 isRetracted "false" @default.
- W4387694665 workType "article" @default.